180 Life Sciences Corp.
ATNF
$1.05
-$0.03-2.78%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -76.31% | -55.66% | -61.17% | -70.54% | -28.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.33% | -49.86% | -56.44% | -74.25% | -12.75% |
| Operating Income | 72.33% | 49.86% | 56.44% | 74.25% | 12.75% |
| Income Before Tax | 93.37% | 100.32% | 77.54% | 94.57% | 41.31% |
| Income Tax Expenses | -- | -- | -- | 99.53% | -- |
| Earnings from Continuing Operations | 91.85% | 100.32% | 77.54% | 94.36% | 52.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.85% | 100.32% | 77.54% | 94.36% | 52.22% |
| EBIT | 72.33% | 49.86% | 56.44% | 74.25% | 12.75% |
| EBITDA | 72.47% | 50.12% | 56.74% | 74.48% | 13.38% |
| EPS Basic | 96.52% | 100.10% | 93.06% | 98.94% | 88.23% |
| Normalized Basic EPS | 89.49% | 98.82% | 93.06% | 94.20% | 66.56% |
| EPS Diluted | 96.52% | 100.07% | 93.04% | 98.94% | 88.23% |
| Normalized Diluted EPS | 89.49% | 98.82% | 93.06% | 94.20% | 66.56% |
| Average Basic Shares Outstanding | 134.31% | 233.85% | 223.68% | 430.58% | 305.92% |
| Average Diluted Shares Outstanding | 134.31% | 233.85% | 223.68% | 430.58% | 305.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
